Reinforcement Learned Automated Anesthesia Systems During Painless Abortion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

167 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-08

Study Completion Date

2027-11-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares the automated anesthesia systems for painless abortion (AAS-PA) with traditional anesthesia in painless abortions. It assesses intraoperative indicators (hypoxemia, injection pain, hypotension, hemodynamics, respiratory depression) and postoperative outcomes (nausea, dizziness, recovery time, satisfaction). The AAS-PA group uses AI-adjusted intravenous ciprofol based on real-time vital signs and sedation depth; the traditional group relies on manual anesthesia. The goal is to verify if AAS-PA safely manages sedation, meets painless standards, reduces adverse events, and improves experience, aiding optimized automated protocols.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patient Preferences in Anesthesia for Abortion Care

NCT03030443

Pregnancy Termination in First Trimester

COMPLETED

Propofol-butorphanol Anesthesia During Uterine Curettage

NCT00795314

Abortion Curettage

COMPLETED PHASE4

Evaluation of Different Anesthesia for Uterine Curettage

NCT00733564

Uterine Curettage Abortion, Induced

COMPLETED NA

The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate

NCT03185156

Nausea and Vomiting

COMPLETED PHASE4

Effects of Repeated Intravenous Anesthesia With Propofol on the Postoperative Neurological Function of Patients Undergoing Hysteroscopic Surgery

NCT05297682

PND Anesthesia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Painless Abortion Artificial Intelligence (AI) Ciprofol

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test group

In the test group, participants will receive anesthesia via an AI model.

Group Type EXPERIMENTAL

AI Controlled General Anesthesia

Intervention Type PROCEDURE

During painless abortion, anesthesia will be induced using ciprofol, and controlled by an AI model.

Control group

In the control group, anesthesia will be induced by experienced anesthesiologists.

Group Type EXPERIMENTAL

General Anesthesia

Intervention Type PROCEDURE

Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AI Controlled General Anesthesia

During painless abortion, anesthesia will be induced using ciprofol, and controlled by an AI model.

Intervention Type PROCEDURE

General Anesthesia

Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18-45 years
* ASA status Ⅰ to Ⅱ
* Diagnosed with early intrauterine pregnancy
* Body mass index (BMI) between 18 to 28 kg/m2

Exclusion Criteria

* History of cardiac, hepatic, renal, or metabolic disorders (e.g., diabetes, hypertension, sleep apnea)
* Known allergy to opioids or ciprofloxacin components
* Cachexia
* History of substance or alcohol abuse
* ASA class III or higher
* Participation in any other drug clinical trial within the past 3 months
* Long-term use of sedative or analgesic medications
* History of neurological disorders and convulsions

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes